5. IDM Pharma webpage;
http://www.idm-biotech.com/. For a EP2101 product description see Products, Science & Technologies/Product Candidates/Products to Prevent Recurrence,
and for interim clinical results open Financial Information & News Desk/News Release to see 06/04/07 IDM Pharma presents interim
Phase II data from EP2101 lung cancer vaccine clinical trial.
6. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of Pox PSA vaccines
(PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Translational
Med. 2006;4:1–5.
7. Favrille webpage;
http://www.favrille.com/ for product information under the Our Technology tab.
8. Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan
R, Nelson WG. Phase I/II trail of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res.
2006;12(11):3394–3401.
9. Hege KM, Jooss K, Pardoll D. GM-CSF gene-modified cancer cell immunotherapies: Of mice and men. Intl Rev of Immunol. 2006;25:321-52.
10. Nestle FO, Farkas A, Conrad C. Dendritic-cell-based vaccination against cancer. Current Opinion Immunol. 2005;17:163–9.
11. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21:873–86.
12. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nature Reviews/Immunol. 2005; 5:296–306.
13. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. J Clin Oncol. 2000;18(23):3894–3903.
14. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. Placebo-controlled
phase III trail of immunologic therapy with Sepuleucel-T (APC8015) in patients with metastatic asymptomatic hormone refractory
prostate cancer. J Clin Oncol. 2006;24(19):3089–94.
15. Dendreon Corporation webpage;
http://www.dendreon.com/ see May 9,2007, Dendreon receives complete response letter form FDA for Provenge biologics license application, under Newsroom/Press
Releases.
16. Su Z, Dannull J, Heiser A, Yancey D, Pruitt S, Madden J, Coleman D, Niedzwiecki D, Gilboa E, Vieweg J. Immunological
and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res.
2003;63:2127–33.
17. Harris J, Monesmith T, Ubben A, Norris M, Freedman JH, Tcherepanova I. An improved RNA amplification procedure results
in increased yield of autologous RNA transfected dendritic cell-based vaccine. Biochim Biophys ACTA. 2005;1724:127–36.
18. IDM Pharma webpage;
http://www.idm-biotech.com/ for the UVIDEM product description see Products, Science & Technologies/Product Candidates/Products to Prevent Recurrence,
and for interim clinical results open Financial Information & News Desk/News Release to see 06/05/07 IDM Pharma presents preliminary
results form Phase II UVIDEM melanoma vaccine clinical trial.
19. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj
N, Pineiro L, Steinman R, Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived
dendritic cell vaccine. Cancer Res. 2001;61:6451–58.
|
